JUDY CLARK: Open Payments
NPI 1770119257 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,760 in 81 payments from 11 companies in 2025. Trend: 2023 $2,264 · 2024 $1,995 · 2025 $2,760
Food & beverage: $2,760
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 13 | $535 |
| ABBVIE INC. | 19 | $402 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $320 |
| Otsuka America Pharmaceutical, Inc. | 14 | $316 |
| Axsome Therapeutics, Inc. | 9 | $298 |
| Alkermes, Inc. | 2 | $233 |
| Neurocrine BioSciences, Inc. | 2 | $223 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $118 |
| Tris Pharma Inc | 1 | $110 |
| Janssen Pharmaceuticals, Inc | 5 | $105 |
Products named: FANAPT, VRAYLAR, CAPLYTA, Auvelity, REXULTI, LYBALVI, INGREZZA, TRINTELLIX.
Industry payments across AL — which companies pay providers there.
